Home  /  Resource Library  /  Rituximab, high-dose methotrexate plus orelabrutinib as induction therapy in newly diagnosed primary central nervous system lymphoma

Rituximab, high-dose methotrexate plus orelabrutinib as induction therapy in newly diagnosed primary central nervous system lymphoma

Results of a study investigating rituximab, methotrexate and orelbrutinib for treatment of PCNSL.